HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany
| Autor: | Brückel, S., Reindl, S. |
|---|---|
| Zdroj: | In Value in Health December 2023 26(12) Supplement:S382-S382 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect